The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Enhancing oncologist knowledge and skills through patient-centric medical education: A collaborative approach with LUNGevity.
 
Kadrin Wilfong
No Relationships to Disclose
 
Michael Beyer
No Relationships to Disclose
 
Upal Kunal Basu Roy
Honoraria - AstraZeneca (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Lilly; Lumanity (Inst)
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); G1 Therapeutics (Inst); Genentech (Inst); Janssen Oncology (Inst); Lilly (Inst); Merck (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Lilly
 
Nikki A. Martin
Stock and Other Ownership Interests - Roche
 
Stephen V. Liu
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Candel Therapeutics; Catalyst Pharmaceuticals; Daiichi Sankyo/UCB Japan; Elevation Oncology; Genentech; Gilead Sciences; Guardant Health; Janssen Oncology; Jazz Pharmaceuticals; Merus; Mirati Therapeutics; MSD Oncology; Novartis; Pfizer; RAPT Therapeutics; Regeneron; Revolution Medicines; Sanofi; Takeda
Research Funding - Abbvie (Inst); Alkermes (Inst); Elevation Oncology (Inst); Ellipses Pharma (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Merck (Inst); Merus (Inst); Nuvalent, Inc. (Inst); OSE Immunotherapeutics (Inst); Puma Biotechnology (Inst); RAPT Therapeutics (Inst); Turning Point Therapeutics (Inst)
 
Dana Wills
No Relationships to Disclose
 
Heather Drew
No Relationships to Disclose